Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa

View ORCID ProfileNicole Wolter, Waasila Jassat, Sibongile Walaza, Richard Welch, Harry Moultrie, Michelle Groome, Daniel Gyamfi Amoako, Josie Everatt, Jinal N. Bhiman, Cathrine Scheepers, Naume Tebeila, Nicola Chiwandire, Mignon du Plessis, Nevashan Govender, Arshad Ismail, Allison Glass, Koleka Mlisana, Wendy Stevens, Florette K. Treurnicht, Zinhle Makatini, Nei-yuan Hsiao, Raveen Parboosing, Jeannette Wadula, Hannah Hussey, Mary-Ann Davies, Andrew Boulle, Anne von Gottberg, View ORCID ProfileCheryl Cohen
doi: https://doi.org/10.1101/2021.12.21.21268116
Nicole Wolter
1Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service, Johannesburg, South Africa
2School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicole Wolter
  • For correspondence: nicolew@nicd.ac.za
Waasila Jassat
3Division of Public Health Surveillance and Response, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sibongile Walaza
1Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service, Johannesburg, South Africa
4School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Welch
3Division of Public Health Surveillance and Response, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harry Moultrie
2School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
5Centre for Tuberculosis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Groome
3Division of Public Health Surveillance and Response, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Gyamfi Amoako
1Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service, Johannesburg, South Africa
6School of Health Sciences, College of Health Sciences, University of KwaZulu-Natal, KwaZulu-Natal, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josie Everatt
1Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinal N. Bhiman
7Centre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa
8SA MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cathrine Scheepers
7Centre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa
8SA MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naume Tebeila
1Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicola Chiwandire
1Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mignon du Plessis
1Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service, Johannesburg, South Africa
2School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nevashan Govender
3Division of Public Health Surveillance and Response, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arshad Ismail
9Sequencing Core Facility, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allison Glass
10Lancet Laboratories, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koleka Mlisana
11National Health Laboratory Service (NHLS), South Africa
12School of Laboratory Medicine and Medical Sciences, University of KwaZulu Natal, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy Stevens
2School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
11National Health Laboratory Service (NHLS), South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florette K. Treurnicht
2School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
11National Health Laboratory Service (NHLS), South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zinhle Makatini
2School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
11National Health Laboratory Service (NHLS), South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nei-yuan Hsiao
11National Health Laboratory Service (NHLS), South Africa
13Division of Medical Virology, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raveen Parboosing
2School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
11National Health Laboratory Service (NHLS), South Africa
14Department of Virology, University of KwaZulu-Natal, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeannette Wadula
2School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
11National Health Laboratory Service (NHLS), South Africa
15Department of Clinical Microbiology & Infectious Diseases, CH Baragwanath Academic Hospital, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hannah Hussey
16Western Cape Government: Health and School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary-Ann Davies
16Western Cape Government: Health and School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Boulle
16Western Cape Government: Health and School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne von Gottberg
1Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service, Johannesburg, South Africa
2School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheryl Cohen
1Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service, Johannesburg, South Africa
4School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cheryl Cohen
  • For correspondence: cherylc@nicd.ac.za
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background The SARS-CoV-2 Omicron variant of concern (VOC) almost completely replaced other variants in South Africa during November 2021, and was associated with a rapid increase in COVID-19 cases. We aimed to assess clinical severity of individuals infected with Omicron, using S Gene Target Failure (SGTF) on the Thermo Fisher Scientific TaqPath COVID-19 PCR test as a proxy.

Methods We performed data linkages for (i) SARS-CoV-2 laboratory tests, (ii) COVID-19 case data, (iii) genome data, and (iv) the DATCOV national hospital surveillance system for the whole of South Africa. For cases identified using Thermo Fisher TaqPath COVID-19 PCR, infections were designated as SGTF or non-SGTF. Disease severity was assessed using multivariable logistic regression models comparing SGTF-infected individuals diagnosed between 1 October to 30 November to (i) non-SGTF in the same period, and (ii) Delta infections diagnosed between April and November 2021.

Results From 1 October through 6 December 2021, 161,328 COVID-19 cases were reported nationally; 38,282 were tested using TaqPath PCR and 29,721 SGTF infections were identified. The proportion of SGTF infections increased from 3% in early October (week 39) to 98% in early December (week 48). On multivariable analysis, after controlling for factors associated with hospitalisation, individuals with SGTF infection had lower odds of being admitted to hospital compared to non-SGTF infections (adjusted odds ratio (aOR) 0.2, 95% confidence interval (CI) 0.1-0.3). Among hospitalised individuals, after controlling for factors associated with severe disease, the odds of severe disease did not differ between SGTF-infected individuals compared to non-SGTF individuals diagnosed during the same time period (aOR 0.7, 95% CI 0.3-1.4). Compared to earlier Delta infections, after controlling for factors associated with severe disease, SGTF-infected individuals had a lower odds of severe disease (aOR 0.3, 95% CI 0.2-0.5).

Conclusion Early analyses suggest a reduced risk of hospitalisation among SGTF-infected individuals when compared to non-SGTF infected individuals in the same time period. Once hospitalised, risk of severe disease was similar for SGTF- and non-SGTF infected individuals, while SGTF-infected individuals had a reduced risk of severe disease when compared to earlier Delta-infected individuals. Some of this reducton is likely a result of high population immunity.

Competing Interest Statement

CC has received grant support from Sanofi Pasteur, Advanced Vaccine Initiative, and payment of travel costs from Parexel. NW, MdP and AvG have received grant support from Sanofi Pasteur. RW declares personal shareholding in the following companies: Adcock Ingram Holdings Ltd, Dischem Pharmacies Ltd, Discovery Ltd, Netcare Ltd, Aspen Pharmacare Holdings Ltd. All other authors declare no conflict of interest.

Funding Statement

This study was funded by the South African Medical Research Council with funds received from the National Department of Health. Sequencing activities for NICD are supported by a conditional grant from the South African National Department of Health as part of the emergency COVID-19 response; a cooperative agreement between the National Institute for Communicable Diseases of the National Health Laboratory Service and the United States Centers for Disease Control and Prevention (grant number 5 U01IP001048-05-00); the African Society of Laboratory Medicine (ASLM) and Africa Centers for Disease Control and Prevention through a sub-award from the Bill and Melinda Gates Foundation grant number INV-018978; the UK Foreign, Commonwealth and Development Office and Wellcome (Grant no 221003/Z/20/Z); the South African Medical Research Council (Reference number SHIPNCD 76756); and the UK Department of Health and Social Care and managed by the Fleming Fund and performed under the auspices of the SEQAFRICA project. The Fleming Fund is a UK aid programme supporting up to 24 low- and middle-income countries (LMICs) generate, share and use data on antimicrobial resistance (AMR) and works in partnership with Mott MacDonald, the Management Agent for the Country and Regional Grants and Fellowship Programme. Screening for SGTF at UCT was supported by the Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), which is supported by core funding from the Wellcome Trust (203135/Z/16/Z and 222754).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Human Research Ethics Committee of the University of the Witwatersrand gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 21, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa
Nicole Wolter, Waasila Jassat, Sibongile Walaza, Richard Welch, Harry Moultrie, Michelle Groome, Daniel Gyamfi Amoako, Josie Everatt, Jinal N. Bhiman, Cathrine Scheepers, Naume Tebeila, Nicola Chiwandire, Mignon du Plessis, Nevashan Govender, Arshad Ismail, Allison Glass, Koleka Mlisana, Wendy Stevens, Florette K. Treurnicht, Zinhle Makatini, Nei-yuan Hsiao, Raveen Parboosing, Jeannette Wadula, Hannah Hussey, Mary-Ann Davies, Andrew Boulle, Anne von Gottberg, Cheryl Cohen
medRxiv 2021.12.21.21268116; doi: https://doi.org/10.1101/2021.12.21.21268116
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa
Nicole Wolter, Waasila Jassat, Sibongile Walaza, Richard Welch, Harry Moultrie, Michelle Groome, Daniel Gyamfi Amoako, Josie Everatt, Jinal N. Bhiman, Cathrine Scheepers, Naume Tebeila, Nicola Chiwandire, Mignon du Plessis, Nevashan Govender, Arshad Ismail, Allison Glass, Koleka Mlisana, Wendy Stevens, Florette K. Treurnicht, Zinhle Makatini, Nei-yuan Hsiao, Raveen Parboosing, Jeannette Wadula, Hannah Hussey, Mary-Ann Davies, Andrew Boulle, Anne von Gottberg, Cheryl Cohen
medRxiv 2021.12.21.21268116; doi: https://doi.org/10.1101/2021.12.21.21268116

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1096)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9772)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2313)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1561)
  • Health Policy (736)
  • Health Systems and Quality Improvement (603)
  • Hematology (238)
  • HIV/AIDS (504)
  • Infectious Diseases (except HIV/AIDS) (11649)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (238)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2144)
  • Nursing (134)
  • Nutrition (337)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1180)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2182)
  • Public and Global Health (4661)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)